Precision Medicine in Oncology® | Specialty

The OncLive Precision Medicine in Oncology® condition center page is a comprehensive resource for clinical news and expert insights on precision-focused approaches in patients with cancer, with gene-targeted tyrosine kinase inhibitors and antibody-drug conjugates, checkpoint inhibitors, tumor-infiltrating lymphocyte therapy, and other tailored treatments. This page features news articles, interviews in written and video format, and podcasts that focus on updates and ongoing research with personalized therapies across solid and hematologic tumors.

Personalizing Cancer Drugs: The Next Front in Diagnostics

October 28th 2015

Less than a decade after the FDA set the ground rules for developing assays that pair molecular targets with new drugs, experts say there have been strides in personalizing anticancer therapies but that many hurdles remain before next-generation sequencing and other precision medicine advances are incorporated into the diagnostic paradigm.

Pazopanib's Activity in Thyroid Cancer Not Predicted by Thyroglobulin

October 22nd 2015

Pazopanib demonstrated significant clinical activity for patients with RAI-refractory differentiated thyroid cancer; however, a predictive biomarker for the therapy could not be uncovered.

Future Directions in Soft Tissue Sarcoma

October 21st 2015

Phase III Data on Eribulin in Advanced STS

October 21st 2015

Early Data With Olaratumab in Soft Tissue Sarcoma

October 21st 2015

Patient Selection in Soft Tissue Sarcoma

October 21st 2015

Use of Trabectedin in Soft Tissue Sarcoma

October 21st 2015

Subtyping in Soft Tissue Sarcoma: The PALLETTE Study

October 21st 2015

Chemotherapy Toxicity Considerations in Soft Tissue Sarcoma

October 21st 2015

Chemotherapy Regimens for Advanced Soft Tissue Sarcoma

October 21st 2015

Importance of Surgery and Radiation in Advanced STS

October 21st 2015

Integrating Community Oncologists Into the Multidisciplinary Team

October 21st 2015

Key Members of the Multidisciplinary Team

October 21st 2015

Implementation of Multidisciplinary Sarcoma Care

October 21st 2015

Multidisciplinary Assessment of Soft Tissue Sarcomas

October 21st 2015

Accurately Diagnosing Soft Tissue Sarcoma

October 21st 2015

Incidence and Subtypes of Advanced Soft Tissue Sarcoma

October 21st 2015

Evidence Builds for Multigene Testing for Hereditary Cancers

October 20th 2015

The use of multigene assays to screen patients for hereditary breast and ovarian cancer risk yields clinically valuable information beyond single-gene BRCA testing, but confusion about accurately interpreting the results presents a challenge for clinicians even as panel testing becomes more widely adopted.

Precision Medicine Carries Significant Challenges but Will (Eventually) Lower Cancer Care Costs and Is the Way to Go (Precisely)

October 19th 2015

Our goal should be to use precision medicine as a way to deliver value-based care.

Dr. Patricia LoRusso on Next-Generation Sequencing Benefit in Metastatic Melanoma Treatment

October 16th 2015

Patricia M. LoRusso, DO, Professor of Medicine and Associate Director of Innovative Medicine, Yale Cancer Center, discusses taking a personalized medicine approach to treat melanoma patients whose tumors do not have BRAF alterations.